The FDA issued an emergency use authorization (EUA) for bebtelovimab, a monoclonal antibody, for the treatment of mild-to-moderate COVID-19 that retains activity against the omicron variant in patients weighing at least 88 pounds who are at high risk of progression to severe COVID-19. This drug is not authorized for hospitalized patients or patients who require oxygen therapy. Bebtelovimab is not a substitute for vaccination.
